Prepping for key ASH presentation, little Aprea Therapeutics gets $57M to fuel PhIII p53 cancer study
Seven months ago, Stockholm-based Aprea Therapeutics managed to remain almost completely overlooked at AACR when the biotech unveiled data from a handful of 8 patients with TP53 Mutant Myelodysplastic Syndromes. Scientists said the study demonstrated a 100% overall response rate for their p53 corrector — APR-246 combined with azacitidine.
Six of the patients had a complete response according to investigators.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.